AMOM1.410%
as of Jul 17
MRNA
GrowthMODERNA INC
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis.
Close · 3M
+6.73%
Held by 4 AI ETFs
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals19
Win rate53% (10/19)
Avg buy return+3.94%
AMOM · Weight decrease · 2d
AMOM, an ETF designed to pick names expected to extend their runs within a ~50 US large cap concentrated momentum sleeve, has steadily reduced its allocation to Moderna following a detected shift in its multi-signal composite. The consecutive weight decreases, from 1.66% to 1.41% over the past week, reflect a system-driven loss of conviction. Despite MRNA's 30-day price return of +19.8%, the AI's holistic assessment, which includes fundamental momentum and earnings revisions, likely identified concerns such as the company’s -29.97% Revenue Growth and -36.73% Return on Equity. This weekly rebalancing fund prioritizes sustained positive momentum, and MRNA’s recent trajectory, despite price gains, no longer meets that criteria.
weight 1.520% → 1.410% (-0.110 pp)·stock up 11.6% in the 30 days before
Jul 17·entry $61.82·now $59.49
-3.77%
since Jul 17
AMOM · Accumulation · 5d
Qraft Technologies' AMOM ETF, which employs a multi-signal momentum composite to pick names expected to extend their runs, gradually increased its MRNA position through its weekly rebalancing process. This concentrated momentum sleeve, holding around 50 US large caps, demonstrates conviction for MRNA's ongoing upward trajectory, despite its negative financial fundamentals. The fund’s AI likely identified signals favoring MRNA's continued climb, given its 1-year return of +197.6% and its current price near the 52-week high. This reflects AMOM's specific methodology of weighing price trends and alternative data to capture extended runs, even at elevated levels.
weight 1.620% → 1.790% (+0.170 pp)·stock up 54.6% in the 30 days before
Jul 7·entry $79.77·now $59.49Fresh
-25.42%
since Jul 7
AMOM · Weight increase · 2d
Moderna's stock currently trades at $69.70, precisely its 52-week high, following substantial returns of +42.1% over 30 days and +168.1% over one year. This strong upward trajectory aligns with Qraft Technologies' AMOM strategy, which targets US large caps expected to extend their runs, leveraging multi-signal momentum. The fund’s decision to increase MRNA's weight to 1.9000% by June 29th, building on gains from June 26th, indicates its algorithm's conviction in the stock's momentum. This sustained allocation occurs even as Moderna reports a negative revenue growth of -29.97% and ROE of -36.73%, alongside a PER of 3.91 and PBR of 1.33. AMOM's design, emphasizing price trends and alternative-data signals within its concentrated momentum sleeve, appears to prioritize the company's consistent price appreciation, which culminates in its 52-week peak.
weight 1.620% → 1.900% (+0.280 pp)·stock up 46.5% in the 30 days before
Jun 29·entry $69.70·now $59.49Fresh
-14.65%
since Jun 29
AMOM · Weight decrease · 2d
MRNA's financial metrics, including a negative revenue growth of -29.97% and a negative ROE of -36.73%, indicate a lack of fundamental momentum, which Qraft Technologies' multi-signal composite considers for its selections. These figures suggest the stock may not meet the manager's criteria for names expected to extend their runs. Despite a 1-year return of +152.2% and MRNA trading at its 52-week high of $67.27, the AI-driven system likely detected that the stock's upward price trend was at an inflection point, with less room for further extension given the weak underlying fundamentals. The consecutive weight decrease on June 24th and 25th from 1.69% to 1.62% for MRNA reflects AMOM's concentrated momentum style, where such position adjustments convey conviction from its analysis. This move demonstrates Qraft's strategy of not simply holding past winners but actively rebalancing weekly based on a composite of signals to identify potential weakening momentum rather than mechanically maintaining a top quintile.
weight 1.700% → 1.620% (-0.080 pp)·stock up 27.0% in the 30 days before
Jun 25·entry $59.75·now $59.49
-0.44%
since Jun 25
AMOM · Accumulation · 5d
MRNA's journey to $60.42, sitting at 94% of its 52-week high after a +117.7% one-year return, clearly signals a stock deeply entrenched in an upward price trend. Qraft's AMOM, specifically designed to identify names expected to extend their runs using a multi-signal momentum composite, would logically detect and respond to such sustained price appreciation. Despite negative revenue growth of -29.97% and a -36.73% ROE, the fund's gradual accumulation of MRNA, moving from 1.41% to 1.74% in its concentrated sleeve, indicates its algorithms are prioritizing the strong price momentum and potentially forward-looking signals over current financial metrics, perhaps also noting the low PER of 3.91 and PBR of 1.33 in this context. This consistent upward adjustment in weighting reflects AMOM's conviction, leveraging its weekly rebalancing to capitalize on perceived ongoing momentum.
weight 1.410% → 1.690% (+0.280 pp)·stock up 28.9% in the 30 days before
Jun 24·entry $60.42·now $59.49Fresh
-1.54%
since Jun 24
AMOM · Accumulation · 5d
The AMOM fund is gradually accumulating Moderna (MRNA), with its daily weight increasing from 1.41% to 1.70% over the specified period. This measured approach aligns with the conviction baked into the fund's concentrated momentum sleeve, specifically as MRNA trades at 95% of its 52-week high after a 1-year return of 120.4%. AMOM's multi-signal momentum composite, designed to pick names expected to extend their runs, is likely detecting continued upward trajectory for the stock. This focus persists even with MRNA's revenue growth at -29.97%, suggesting the fund's models prioritize other drivers like its low PER of 3.91 or alternative-data signals.
weight 1.430% → 1.700% (+0.270 pp)·stock up 29.1% in the 30 days before
Jun 23·entry $61.00·now $59.49Fresh
-2.48%
since Jun 23
AMOM · Accumulation · 5d
Between June 10 and June 18, AMOM incrementally increased its allocation to MRNA from 1.40% to 1.74%, before a minor reduction to 1.58% by June 22. This activity reflects Qraft's multi-signal momentum composite, which likely identified MRNA's substantial price ascent—including a 90-day return of 46.5% and approaching its 52-week high of $63.96—as a candidate expected to extend its run. Such a sustained, albeit uneven, increase in weight for a stock already trading at $59.34, 93% of its annual high, demonstrates the concentrated conviction characteristic of AMOM's design, where position changes are intentionally meaningful. Despite MRNA's reported negative revenue growth and ROE figures, AMOM's weekly rebalancing and multi-signal approach likely weigh MRNA's strong price trends and alternative data signals, alongside any perceived shifts in fundamental momentum, to justify this Health Care sector accumulation.
weight 1.400% → 1.580% (+0.180 pp)·stock up 23.3% in the 30 days before
Jun 22·entry $59.34·now $59.49Fresh
+0.24%
since Jun 22
AMOM · Accumulation · 5d
Despite MRNA reporting negative revenue growth of -29.97% and a negative ROE of -36.73%, Qraft's AMOM ETF pursued a gradual accumulation of the stock, indicating its multi-signal momentum composite likely prioritized factors beyond traditional profitability to identify names expected to extend their runs. This accumulation, moving MRNA's weight from 1.41% to 1.74% over roughly a week, coincided with the stock trading at its 52-week high of $63.96 after seeing a 30-day return of +31.8% and a 90-day return of +52.3%. The consistent daily increases in MRNA's allocation reflect AMOM's concentrated momentum sleeve, where position changes carry conviction by design, signaling strong indications from its price trends, earnings revisions, fundamental momentum, or alternative-data signals.
weight 1.410% → 1.740% (+0.330 pp)·stock up 39.9% in the 30 days before
Jun 18·entry $63.96·now $59.49Fresh
-6.99%
since Jun 18
AMOM · Accumulation · 5d
MRNA currently trades at $63.96, the top of its 52-week range, having delivered a +31.8% return over the last 30 days and a +132.9% return over the past year. This sustained upward price trajectory likely triggered AMOM's multi-signal momentum composite, which prioritizes names expected to extend their runs rather than mechanically holding top performers. Despite MRNA's negative revenue growth of -29.97% and a -36.73% return on equity, the AI-managed ETF likely found the strong price trends, possibly augmented by positive earnings revisions or alternative data signals, compelling enough. Qraft Technologies' concentrated momentum sleeve then initiated a gradual accumulation of MRNA, increasing its weight from 1.39% to 1.72% over several days in mid-June, reflecting conviction that momentum signals indicate further upside potential.
weight 1.390% → 1.720% (+0.330 pp)·stock up 28.5% in the 30 days before
Jun 17·entry $61.80·now $59.49Fresh
-3.74%
since Jun 17
AMOM · Weight increase · 2d
Moderna's weight in AMOM registered a consecutive increase on June 15th and 16th, culminating in a significant jump to 1.55% from a fluctuating range around 1.4%. This movement suggests Qraft's multi-signal momentum composite detected reinforcing trends for MRNA, currently trading at $55.40 and within 4% of its 52-week high after a 103.2% return over the past year. The fund, which seeks names expected to extend their runs, likely prioritized these strong price trends and perhaps alternative-data signals over the negative revenue growth and ROE present in Moderna's financial summary. Such a deliberate and stepped increase, within AMOM's concentrated momentum sleeve and weekly rebalancing, reflects a strengthening conviction in Moderna's continued upward trajectory.
weight 1.410% → 1.550% (+0.140 pp)·stock up 13.0% in the 30 days before
Jun 16·entry $55.40·now $59.49Drifting
+7.38%
since Jun 16
AMOM · Weight decrease · 2d
weight 1.440% → 1.390% (-0.050 pp)·stock down 1.9% in the 30 days before
Jun 8·entry $47.60·now $59.49
+24.98%
since Jun 8
AMOM · Weight increase · 3d
weight 0 → 1.440% (new)·stock up 10.4% in the 30 days before
Jun 4·entry $51.59·now $59.49Chased
+15.31%
since Jun 4
+21.26%
since Jun 3
+30.35%
since Jun 2
LQAI · Weight decrease · 2d
The Qraft AI engine managing LQAI has exhibited a consistent, gradual reduction in MRNA's weight, notably dropping from 0.87% to 0.80% between July 15th and 17th, a series of daily consecutive decreases. This measured trimming occurs even as MRNA's stock shows significant recent price strength, with a 30-day return of 19.8% and a 1-year return of 106.8%. Given LQAI's strategy as a core large-cap fund that selects names without a heavy factor tilt, the AI is likely not solely driven by this price momentum, but also factoring in MRNA's underlying financial challenges. MRNA's negative revenue growth of -29.97% and negative ROE of -36.73% suggest that as the stock's price reached 76% of its 52-week high, the Qraft AI's ranking algorithm deemed the current allocation increasingly incongruous with a balanced, fundamental assessment, prompting these weekly-rebalancing-enabled daily adjustments.
weight 0.870% → 0.800% (-0.070 pp)·stock up 11.6% in the 30 days before
Jul 17·entry $61.82·now $59.49
-3.77%
since Jul 17
LQAI · New entry · 1d
LQAI, managed by the LG-Qraft collaboration and leveraging Qraft's AI ranking for its approximately 100 US large-cap portfolio, initiated a position in MRNA during its weekly rebalance on July 7th. This AI-driven selection method, designed without a heavy factor tilt and positioned midway between broad and concentrated momentum styles, likely identified MRNA's compelling price action despite its challenging financial summary. While MRNA reported revenue growth of -29.97% and a negative ROE, the stock demonstrated a substantial 30-day return of +70.2% and is currently trading at $79.77, near its 52-week high. The Qraft engine's decision to include MRNA at a 1.01% weight suggests its algorithm prioritizes recent market momentum as a key signal for dynamic portfolio adjustments.
weight 0 → 1.010% (new)·stock up 54.6% in the 30 days before
Jul 7·entry $79.77·now $59.49Fresh
-25.42%
since Jul 7
BUZZ · New entry · 1d
weight 0 → 0.320% (new)·stock up 21.1% in the 30 days before
Jul 16·entry $63.15·now $59.49Fresh
-5.80%
since Jul 16
BUZZ · Exit · 1d
The VanEck BUZZ ETF, which utilizes NLP over social media, blogs, and news to rank stocks by positive-sentiment intensity, removed Moderna (MRNA) from its portfolio. This change reflects the fund's algorithmic methodology rather than active management, as its index rebalances monthly for its ~75 large/mid cap holdings. Despite MRNA's significant +110.9% 1-year return and its current price at 93% of its 52-week high, the complete removal on 2026-06-18 indicates a sufficient drop in the intensity of positive crowd sentiment captured by the ETF's system. Such a decline in positive social interest could plausibly arise when strong price performance coexists with challenging fundamentals, like MRNA's -29.97% revenue growth, eventually dampening the overall online buzz.
weight 0.530% → 0 (exited)·stock up 39.9% in the 30 days before
Jun 18·entry $63.96·now $59.49
-6.99%
since Jun 18
BUZZ · Accumulation · 5d
VanEck's BUZZ, an algorithmic sentiment tracker utilizing NLP across social media, blogs, and news, likely detected escalating positive chatter surrounding Moderna (MRNA). The ETF's methodology, which passively ranks and holds approximately 75 US stocks based on sentiment intensity, led to a gradual accumulation of MRNA, with its weight increasing from 0.4000% to 0.5300% over several days. This upward adjustment in holdings is consistent with MRNA's significant price momentum, marked by a +132.9% 1-year return, which often fuels retail interest even when core financials like revenue growth remain negative.
weight 0.400% → 0.530% (+0.130 pp)·stock up 28.5% in the 30 days before
Jun 17·entry $61.80·now $59.49Fresh
-3.74%
since Jun 17
BUZZ · Weight increase · 2d
MRNA's financial profile, with a PER of 3.91, PBR of 1.33, and significant negative figures for revenue growth (-29.97%) and ROE (-36.73%), presents a picture not driven by traditional value or growth metrics. For the BUZZ ETF, however, its algorithmic sentiment tracking methodology, based on NLP analysis of social media, blogs, and news, prioritizes public perception and positive discourse over fundamental financial health. The consecutive increases in MRNA's weight within BUZZ, moving from 0.41% on June 9th to 0.47% by June 16th, closely followed the stock's ascent to its 52-week high of $61.80, reflecting its +26.7% 30-day and +47.3% 90-day returns. This sustained price appreciation likely generated a significant volume of positive sentiment online, which the ETF's NLP system identified as a heightened sentiment intensity for MRNA, triggering the subsequent, mechanically-driven portfolio adjustments during its monthly rebalancing.
weight 0.430% → 0.470% (+0.040 pp)·stock up 13.0% in the 30 days before
Jun 16·entry $55.40·now $59.49Drifting
+7.38%
since Jun 16
BUZZ · Weight decrease · 2d
MRNA, currently trading at $47.73 and 83% of its 52-week high, has seen its price climb +83.2% over the last year, with recent 30- and 90-day returns also positive. As an algorithmic sentiment tracker, BUZZ directly reflects the aggregate positive sentiment gathered from social media, news, and blogs, rebalancing monthly based on these signals. The observed consecutive weight decrease for MRNA from May 28 to June 1, despite positive recent price momentum, indicates a potential cooling or diversification of positive retail-driven discussion around the stock following its prior upward movement near its 52-week peak. MRNA’s financial summary, showing negative revenue growth of -29.97% and a negative ROE of -36.73%, alongside a PER of 3.91 and PBR of 1.33, likely contributes to a dynamic sentiment profile that can shift rapidly. The subsequent increase in BUZZ's MRNA weighting on June 3-4 then suggests a renewed surge in positive social sentiment, aligning with its retail-crowd signal methodology, before a slight pull-back, illustrating the often-volatile nature of crowd-sourced enthusiasm on a stock experiencing significant price movement.
weight 0.420% → 0.400% (-0.020 pp)·stock down 1.9% in the 30 days before
Jun 8·entry $47.60·now $59.49
+24.98%
since Jun 8
BUZZ · Weight increase · 2d
weight 0.360% → 0.420% (+0.060 pp)·stock up 10.4% in the 30 days before
Jun 4·entry $51.59·now $59.49Chased
+15.31%
since Jun 4
+29.16%
since Jun 1
+26.06%
since May 29
+25.88%
since May 21
+15.78%
since Mar 20
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.